MorphoSys AG (MorphoSys AG) Change In Inventory : $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is MorphoSys AG Change In Inventory?

MorphoSys AG's change in inventory for the quarter that ended in Dec. 2023 was $0.0 Mil. It means MorphoSys AG's inventory stayed the same from Sep. 2023 to Dec. 2023 .

MorphoSys AG's change in inventory for the fiscal year that ended in Dec. 2023 was $0.0 Mil. It means MorphoSys AG's inventory stayed the same from Dec. 2022 to Dec. 2023 .

MorphoSys AG's Total Inventories for the quarter that ended in Dec. 2023 was $67.7 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. MorphoSys AG's Days Inventory for the quarter that ended in Dec. 2023 was 193.25.

Inventory Turnover measures how fast the company turns over its inventory within a year. MorphoSys AG's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.47.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. MorphoSys AG's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.53.

MorphoSys AG Change In Inventory Historical Data

The historical data trend for MorphoSys AG's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Change In Inventory Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-4.91

-10.32

-34.29

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

MorphoSys AG Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

MorphoSys AG (NAS:MOR) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

MorphoSys AG's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	33.843	/	15.98	*	365 / 4
	=	193.25

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

MorphoSys AG's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	15.98	/	33.843
	=	0.47

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

MorphoSys AG's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	33.843	/	64.425
	=	0.53

MorphoSys AG Change In Inventory Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (MorphoSys AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (NAS:MOR) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

MPSYF:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.